Yi June Kim

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia

S. Colla, G. Garcia-Manero, Koichi Takahashi, 2023, bioRxiv.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

S. Colla, R. Kanagal-Shamanna, Hui Yang, 2024, Cell reports. Medicine.